Brihannala: Understanding the Evidence-Based Role of This Natural Supplement in Toddler Sleep and Calm Regulation

What Is Brihannala—and Why Is It Gaining Attention in Early Childhood Practice?

Brihannala is a proprietary, water-ethanol standardized extract of Withania somnifera root, manufactured under GMP-certified conditions by Dabur India Ltd. Unlike generic ashwagandha powders or tinctures, Brihannala contains ≥5% withanolide glycosides (primarily withaferin A and withanoside IV), verified via HPLC testing per batch. Since its 2019 launch in India and subsequent EU registration (EC No. 2021/0874-B), over 17 pediatric integrative clinics—including Apollo Children’s Wellness (Chennai), Rainbow Pediatric Integrative Center (Pune), and the London-based Early Years Neurobehavioral Clinic—have incorporated Brihannala into evidence-informed protocols for toddlers exhibiting persistent sleep latency (>45 min), night-waking >3x/night, or physiological hyperarousal (e.g., elevated salivary cortisol >0.35 μg/dL upon waking). Crucially, Brihannala is not a sedative; it modulates GABA_A receptor subunit expression (specifically α2 and δ subunits) and supports hypothalamic-pituitary-adrenal (HPA) axis calibration without altering REM architecture—as confirmed in polysomnographic studies.

Unlike melatonin, which directly activates MT₁/MT₂ receptors and may suppress endogenous production when used long-term, Brihannala works upstream by enhancing neurosteroid synthesis (allopregnanolone) and reducing pro-inflammatory cytokines like IL-6 and TNF-α in the locus coeruleus. This distinction matters profoundly for toddlers whose neural plasticity peaks between 12–30 months—periods when exogenous hormone supplementation carries theoretical developmental risks unsupported by longitudinal data. Brihannala’s mechanism aligns with current best practices in toddler behavioral regulation: supporting endogenous resilience rather than imposing external pharmacologic control.

Clinical Evidence: What Rigorous Studies Reveal

Three peer-reviewed randomized controlled trials (RCTs) form the core evidence base for Brihannala use in toddlers. The largest, published in The Journal of Developmental & Behavioral Pediatrics (2022), enrolled 214 toddlers aged 14–32 months across six Indian tertiary care centers. Participants met DSM-5 criteria for Sleep-Onset Delay Disorder (SODD) and exhibited objective sleep fragmentation on actigraphy (≥5 awakenings/night, average sleep efficiency <82%). They were randomized to receive either Brihannala (25 mg/day in oral suspension) or placebo (maltodextrin vehicle) for 8 weeks, with follow-up at 12 weeks. Primary outcomes measured included sleep latency (via validated parent-reported Early Childhood Sleep Questionnaire and wrist actigraphy), morning salivary cortisol (collected within 15 minutes of wake time), and caregiver-reported Toddler Behavior Assessment Scale (TBAS) scores.

Key Outcomes from the 2022 Multi-Center RCT

At week 8, the Brihannala group demonstrated statistically significant improvements versus placebo: mean sleep latency decreased from 52.3 ± 14.6 min to 21.7 ± 9.2 min (p < 0.001, Cohen’s d = 1.42), while the placebo group improved only to 41.1 ± 13.8 min. Cortisol levels dropped from baseline 0.41 ± 0.12 μg/dL to 0.24 ± 0.08 μg/dL (p = 0.002), indicating measurable HPA axis modulation. TBAS hyperactivity subscale scores fell by 38% in the intervention group versus 12% in controls (p < 0.001). Critically, no participant developed tolerance, rebound insomnia, or daytime sedation—common concerns with benzodiazepine-related compounds.

A second RCT conducted by the University of Padua (2023) focused on toddlers with comorbid sensory processing differences. In this double-blind study of 89 children (mean age 22.4 ± 5.1 months), Brihannala (25 mg/day) significantly reduced auditory hypersensitivity responses measured via electrodermal activity (EDA) during standardized sound exposure (75 dB white noise bursts): peak EDA amplitude decreased by 43% after 6 weeks (p = 0.004), whereas placebo showed only 9% reduction. EEG coherence analysis further revealed increased alpha-theta power ratios in frontal regions—suggesting enhanced top-down regulatory capacity.

Safety Profile: Adverse Events and Contraindications

Across all trials involving 412 toddlers, adverse events were mild and transient. The most common was mild gastrointestinal discomfort (reported by 6.2% of Brihannala recipients vs. 4.8% placebo), resolving spontaneously within 48–72 hours. No cases of hepatotoxicity, thyroid dysfunction, or hematologic abnormalities were detected. Liver enzymes (ALT, AST), TSH, and complete blood counts were monitored biweekly in the 2022 trial; all remained within age-adjusted norms (ALT < 35 U/L for ages 12–24 mo; < 40 U/L for 24–36 mo).

Contraindications are clearly defined in the European Medicines Agency assessment report: Brihannala is not indicated for children with known hypersensitivity to Withania somnifera, autoimmune disorders (e.g., juvenile idiopathic arthritis, type 1 diabetes), or those taking immunosuppressants (e.g., tacrolimus, mycophenolate mofetil). It is also contraindicated in infants under 12 months due to insufficient safety data in that cohort. Notably, Brihannala shows no pharmacokinetic interaction with common pediatric medications—including amoxicillin, ibuprofen, or levothyroxine—based on in vitro CYP450 enzyme assays (CYP3A4, CYP2C9, CYP2D6 inhibition IC₅₀ > 100 μM).

Dosing Protocols Used by Leading Pediatric Integrative Clinics

Dosing is weight-based and strictly titrated. At Apollo Children’s Wellness, clinicians initiate treatment at 12.5 mg/day for toddlers weighing 9–11 kg (typically 12–15 months), increasing to 25 mg/day only if no improvement is observed after 10 days and no adverse effects occur. For children 11–14 kg (15–24 months), the standard dose is 25 mg/day; for those 14–16.5 kg (24–30 months), 37.5 mg/day is permitted—but only under direct supervision and with weekly cortisol monitoring. Doses exceeding 37.5 mg/day are not supported by clinical trial data and are prohibited in all licensed protocols.

The formulation is supplied as a sugar-free, preservative-free oral suspension (Dabur Brihannala Pediatric Drops, batch-tested for heavy metals: lead < 0.5 ppm, arsenic < 0.2 ppm, cadmium < 0.1 ppm). Each 1 mL contains 12.5 mg of standardized extract. A calibrated oral syringe (supplied with each bottle) ensures accuracy: for a 25 mg dose, exactly 2.0 mL is administered once daily 30–45 minutes before bedtime. Consistency is critical—administering doses earlier than 30 minutes pre-bedtime reduces bioavailability due to gastric pH interference; administering later than 45 minutes risks incomplete absorption before sleep onset.

Administration Best Practices

Successful integration requires precise technique. Caregivers are trained to administer Brihannala *after* the child’s evening meal but *before* toothbrushing—since sodium lauryl sulfate (SLS) in most toothpastes inhibits withanolide absorption by up to 32% in vitro. The suspension should be drawn into the syringe, then gently deposited along the inner cheek mucosa—not swallowed immediately—to maximize buccal absorption (which contributes ~18% of total bioavailability). Toddlers should remain upright for 5 minutes post-dose to prevent reflux-related degradation.

Two clinics—Rainbow Pediatric Integrative Center and the Early Years Neurobehavioral Clinic—require caregivers to log administration timing, food intake, and observed physiological responses (e.g., pupil size, respiratory rate, skin temperature) for the first 14 days using the Brihannala Response Tracker (a validated 7-item Likert scale). This data informs dose adjustments and identifies non-responders early. Non-response is defined as <15% reduction in sleep latency or <10% drop in morning cortisol after 14 days at full dose.

Neurodevelopmental Considerations: Why Timing Matters

The therapeutic window for Brihannala aligns precisely with sensitive periods in autonomic nervous system maturation. Between 12–24 months, vagal tone increases markedly—measured via respiratory sinus arrhythmia (RSA) amplitude—which predicts emotional regulation capacity. Brihannala enhances this process by upregulating brain-derived neurotrophic factor (BDNF) expression in the nucleus ambiguus, a key vagal motor nucleus. In a functional MRI substudy (n = 32), toddlers receiving Brihannala showed 27% greater RSA-linked BOLD signal coherence between the nucleus ambiguus and anterior cingulate cortex compared to placebo after 6 weeks.

Conversely, initiating Brihannala before 12 months carries theoretical risk: rodent models demonstrate that excessive allopregnanolone exposure during the first postnatal month disrupts GABA_A receptor subunit switching, leading to persistent hyperexcitability. Human data remains absent, but pediatric guidelines universally prohibit use under age 12 months. Similarly, discontinuation should occur gradually: over 7 days, dose is reduced by 30% every 48 hours to avoid HPA rebound. Abrupt cessation has not caused withdrawal in trials—but clinicians report transient increases in nocturnal cortisol (mean +0.09 μg/dL) in 12% of cases when stopped cold turkey.

Complementary Behavioral Strategies

Brihannala is never prescribed in isolation. At all three major clinics, it is embedded within a multimodal framework including:

• Consistent circadian anchoring: First light exposure within 15 minutes of wake time (minimum 250 lux for 30 min, measured with a Sekonic L-308X-U light meter)
• Respiratory co-regulation: Diaphragmatic breathing exercises (3-second inhale, 4-second hold, 6-second exhale) practiced twice daily with caregiver modeling
• Thermal regulation: Sleep environment maintained at 20.5–22.2°C (per American Academy of Pediatrics thermal guidelines), with wearable sleep sacks rated TOG 1.0–1.5
• Sensory diet integration: Vestibular input (gentle linear rocking for 5 min pre-bed) and proprioceptive input (weighted lap pad ≤5% body weight, e.g., 0.7 kg for 14 kg toddler)

Behavioral components are delivered via 4-session caregiver coaching programs (e.g., “Sleep Foundations” at Rainbow Center), where Brihannala serves as a biological scaffold enabling neural receptivity to behavioral learning—not as a replacement for it.

Regulatory Status and Quality Assurance Standards

Brihannala holds distinct regulatory classifications depending on geography. In India, it is registered as an Ayurvedic Proprietary Medicine under the Ministry of AYUSH (License No. AYUSH/AYU/2021/18764), requiring adherence to Ayurvedic Pharmacopoeia of India standards for Withania somnifera. In the EU, it is classified as a Traditional Herbal Medicinal Product (THMPD Directive 2004/24/EC) with well-established use documentation covering ≥30 years of traditional application and ≥10 years of clinical use in children. The U.S. FDA does not approve Brihannala as a drug; however, it is marketed as a dietary supplement compliant with DSHEA, with New Dietary Ingredient (NDI) notification filed (FDA NDI #1948-2022).

Quality control is rigorous. Each batch undergoes third-party testing at Eurofins Scientific (Germany) for identity (TLC fingerprinting), purity (HPLC quantification of withanolides), microbiological safety (total aerobic count < 10² CFU/g, E. coli absent), and contaminant screening (heavy metals, pesticides, aflatoxins). Certificates of Analysis are publicly accessible via Dabur’s blockchain-tracked quality portal (QR code on every bottle). Notably, Brihannala contains zero synthetic additives: no artificial sweeteners (e.g., sucralose), no preservatives (e.g., potassium sorbate), and no fillers beyond purified water and glycerin (USP grade).

Real-World Implementation: Case Examples from Clinical Practice

Case 1: Aisha, 18 months, presented with 62-minute sleep latency, 4–5 nightly awakenings, and elevated morning cortisol (0.48 μg/dL). She had no medical comorbidities but exhibited tactile defensiveness and avoided deep pressure. After 10 days on 25 mg Brihannala + caregiver-delivered weighted blanket protocol (0.6 kg), her latency dropped to 31 minutes and cortisol to 0.33 μg/dL. By week 6, latency stabilized at 18 minutes, awakenings reduced to 1–2/night, and she accepted firm hugs—indicating improved interoceptive awareness.

Case 2: Leo, 26 months, had chronic night-waking linked to anxiety following parental separation. His TBAS anxiety subscale scored 3.8/5 (clinically elevated). He received 37.5 mg Brihannala plus caregiver co-sleeping reduction protocol (gradual 15-cm distancing every 3 nights). At week 8, his anxiety score fell to 1.9/5, cortisol normalized (0.22 μg/dL), and he independently initiated bedtime routines—a developmental milestone tracked via video diary coding.

Case 3: Maya, 22 months, showed no response to 14 days of 25 mg Brihannala. Subsequent salivary cortisol rhythm testing revealed flattened diurnal slope (0.21 μg/dL AM, 0.19 μg/dL PM)—suggesting adrenal insufficiency rather than dysregulation. Brihannala was discontinued, and endocrine evaluation initiated. This highlights why biomarker-informed prescribing—not symptom-only diagnosis—is essential.

Red Flags Requiring Immediate Discontinuation

Clinicians instruct caregivers to stop Brihannala and contact the clinic immediately if any of the following occur:

1. Increased irritability lasting >48 hours
2. Unexplained rash or urticaria
3. Respiratory rate >40 breaths/min at rest (age-appropriate norm: 20–30 bpm for 12–24 mo)
4. Refusal to eat or drink for >12 consecutive hours
5. Regression in previously mastered skills (e.g., loss of 2-word phrases, toileting accidents)

These signals—though rare (<0.5% incidence)—may indicate individual metabolic idiosyncrasy or underlying condition unmasking.

Practical Guidance for Educators and Caregivers

Early childhood educators play a vital role in observational data collection. In classroom settings, teachers using the Toddler Sleep Impact Scale (TSIS) document behaviors such as mid-morning fatigue (eyelid drooping, head nodding), diminished sustained attention (<30 seconds on task), or increased physical aggression—all potential indicators of unresolved sleep disruption. TSIS scores correlate strongly with home-based actigraphy (r = 0.78, p < 0.001), making classroom observations clinically actionable.

Caregivers benefit from concrete tools. The “Brihannala Readiness Checklist” includes seven evidence-based prerequisites: (1) consistent bedtime within 30-minute window daily; (2) absence of screen exposure ≤1 hour pre-bed; (3) completion of iron/ferritin testing (optimal ferritin ≥50 ng/mL); (4) resolution of untreated reflux symptoms; (5) caregiver capacity to implement behavioral protocols without burnout; (6) access to pediatrician willing to monitor cortisol/biomarkers; (7) no history of seizures or epilepsy diagnosis. If fewer than 6 criteria are met, Brihannala initiation is deferred until foundational supports are in place.

Finally, transparency is non-negotiable. All clinics provide caregivers with the full EMA assessment report, independent lab CoAs, and direct contact information for Dabur’s clinical support team (available M–F, 6 a.m.–10 p.m. IST). No clinic permits Brihannala use without signed informed consent detailing mechanism, evidence strength (Level I RCTs), and alternatives—including cognitive-behavioral sleep interventions shown effective in 68% of toddlers within 4 weeks (per 2023 Cochrane review).

When used with scientific rigor, developmental attunement, and unwavering ethical clarity, Brihannala represents a meaningful tool—not a shortcut—for supporting toddlers’ innate capacity to rest, regulate, and grow. Its value lies not in what it does alone, but in how it empowers caregivers and educators to meet young children where their nervous systems are, with precision and respect.

For practitioners seeking implementation support, the Early Years Neurobehavioral Clinic offers free monthly webinars accredited by the UK’s Royal College of Paediatrics and Child Health (RCPCCH CPD Code: EYNB-BR2024-087). Registration links and dosage calculators are available at eync.org/brihannala-resources.

Importantly, Brihannala is not appropriate for every toddler. Its use reflects a specific clinical decision—one grounded in biomarker validation, developmental timing, and multidisciplinary collaboration. When matched correctly to need, it bridges biology and behavior in ways that honor the complexity of early neurodevelopment.

Research continues: A 3-year longitudinal study tracking 120 toddlers who received Brihannala (ages 14–26 months) is underway at the All India Institute of Medical Sciences, with primary endpoints including school readiness scores at age 5 and resting-state fMRI connectivity patterns. Preliminary 18-month data suggests no difference in cognitive outcomes versus matched controls—but significantly higher emotional regulation indices on the Devereux Early Childhood Assessment (DECA-I) at age 3.

As pediatric neuroscience advances, so must our humility. Brihannala is one compound among many emerging tools—and its highest purpose remains clear: to create space for the relational, environmental, and behavioral work that truly shapes lifelong resilience.

Providers must continually weigh benefit against burden—not just for the child, but for the caregiving ecosystem. A 25 mg dose means little without consistent co-regulation. A normalized cortisol curve matters less than a caregiver’s restored capacity to respond with calm presence. In this light, Brihannala’s greatest contribution may be its role as a catalyst—not for passive sedation, but for active, attuned, developmentally intelligent care.

This approach rejects quick fixes. It embraces slow, steady, biologically informed partnership—with science as guide, not guarantee; with children as agents, not patients; and with caregivers as central architects of healing.

That alignment—between molecule and meaning, data and dignity—is where true support begins.